Grifols appoints new CEO; founding family members to leave executive roles
Trade with 70% Backtested Accuracy
Analyst Views on GRFS
About GRFS
About the author
Grifols Obtains FDA Approval to Introduce Fesilty in the US by Mid-2026
FDA Approval: Grifols, S.A. has received FDA approval for Fesilty, a human fibrinogen product aimed at treating acute bleeding in patients with congenital fibrinogen deficiency.
Launch Timeline: The product is expected to be launched in the U.S. in the first half of 2026.
Company Statement: Dr. Jörg Schüttrumpf, CEO of Biotest AG, expressed pride in their contribution to enhancing access to life-saving fibrinogen therapies globally.
Stock Performance: Grifols' stock (GRFS) is currently trading at $8.99, reflecting a 0.84 percent increase on the Nasdaq.
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - November 26, 2025
Validea's Upgrades: Today's upgrades for Validea's Book/Market Investor model highlight significant changes in ratings for stocks like Grifols SA, Invesco Ltd, and Molson Coors Beverage Co, reflecting improved fundamentals and valuations.
Grifols SA: The stock rating for Grifols SA increased from 0% to 90%, indicating strong interest based on its financial health and valuation in the biotechnology sector.
Invesco Ltd: Invesco Ltd's rating improved from 0% to 80%, suggesting a positive outlook based on its fundamentals in the investment services industry.
Molson Coors Beverage Co: Molson Coors Beverage Co saw its rating rise from 0% to 90%, demonstrating strong interest due to its financial performance in the alcoholic beverages market.
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - October 10, 2025
Validea's Upgrade: Validea's Book/Market Investor model, based on Joseph Piotroski's strategy, upgraded Grifols SA (GRFS) from 0% to 90%, indicating strong interest due to improved fundamentals and stock valuation.
Company Overview: Grifols SA is a Spanish pharmaceutical company specializing in plasma-derived medicines, organized into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others, focusing on both therapeutic and non-therapeutic biological products.
Everything You Should Know About Grifols (GRFS) Upgrade to Buy Rating
Grifols Upgrade: Grifols (GRFS) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which can influence stock prices.
Earnings Estimates Impact: The Zacks rating system focuses on changes in earnings estimates, which are strongly correlated with near-term stock movements, making it a valuable tool for investors.
Analyst Consensus: Over the past three months, analysts have raised their earnings estimates for Grifols, reflecting an improvement in the company's underlying business and potential for stock price increase.
Zacks Rating System: The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% receiving "Strong Buy" or "Buy" ratings, suggesting that Grifols is positioned for market-beating returns.
Grifols S.A. declares $0.1404 dividend
Dividend Declaration: Grifols S.A. has declared a dividend of $0.1404 per share, with a forward yield of 5.25%.
Payment Details: The dividend is payable on August 20 for shareholders recorded by August 12, with the ex-dividend date also set for August 12.
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
U.S. Stock Market Performance: U.S. stocks rose on Wednesday, with the Dow Jones index increasing by 0.1%, while Verona Pharma's shares surged 20.6% following Merck's announcement of a $10 billion acquisition deal.
Notable Stock Gains: Several companies saw significant stock price increases, including Scage Future (up 55.4%), ProKidney Corp (up 47.1%), and Rhythm Pharmaceuticals (up 25.8%) after positive trial results.
Grifols Obtains FDA Approval to Introduce Fesilty in the US by Mid-2026
FDA Approval: Grifols, S.A. has received FDA approval for Fesilty, a human fibrinogen product aimed at treating acute bleeding in patients with congenital fibrinogen deficiency.
Launch Timeline: The product is expected to be launched in the U.S. in the first half of 2026.
Company Statement: Dr. Jörg Schüttrumpf, CEO of Biotest AG, expressed pride in their contribution to enhancing access to life-saving fibrinogen therapies globally.
Stock Performance: Grifols' stock (GRFS) is currently trading at $8.99, reflecting a 0.84 percent increase on the Nasdaq.
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - November 26, 2025
Validea's Upgrades: Today's upgrades for Validea's Book/Market Investor model highlight significant changes in ratings for stocks like Grifols SA, Invesco Ltd, and Molson Coors Beverage Co, reflecting improved fundamentals and valuations.
Grifols SA: The stock rating for Grifols SA increased from 0% to 90%, indicating strong interest based on its financial health and valuation in the biotechnology sector.
Invesco Ltd: Invesco Ltd's rating improved from 0% to 80%, suggesting a positive outlook based on its fundamentals in the investment services industry.
Molson Coors Beverage Co: Molson Coors Beverage Co saw its rating rise from 0% to 90%, demonstrating strong interest due to its financial performance in the alcoholic beverages market.
Daily Upgrade Report for Validea's Joseph Piotroski Strategy - October 10, 2025
Validea's Upgrade: Validea's Book/Market Investor model, based on Joseph Piotroski's strategy, upgraded Grifols SA (GRFS) from 0% to 90%, indicating strong interest due to improved fundamentals and stock valuation.
Company Overview: Grifols SA is a Spanish pharmaceutical company specializing in plasma-derived medicines, organized into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others, focusing on both therapeutic and non-therapeutic biological products.
Everything You Should Know About Grifols (GRFS) Upgrade to Buy Rating
Grifols Upgrade: Grifols (GRFS) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which can influence stock prices.
Earnings Estimates Impact: The Zacks rating system focuses on changes in earnings estimates, which are strongly correlated with near-term stock movements, making it a valuable tool for investors.
Analyst Consensus: Over the past three months, analysts have raised their earnings estimates for Grifols, reflecting an improvement in the company's underlying business and potential for stock price increase.
Zacks Rating System: The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% receiving "Strong Buy" or "Buy" ratings, suggesting that Grifols is positioned for market-beating returns.
Grifols S.A. declares $0.1404 dividend
Dividend Declaration: Grifols S.A. has declared a dividend of $0.1404 per share, with a forward yield of 5.25%.
Payment Details: The dividend is payable on August 20 for shareholders recorded by August 12, with the ex-dividend date also set for August 12.
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
U.S. Stock Market Performance: U.S. stocks rose on Wednesday, with the Dow Jones index increasing by 0.1%, while Verona Pharma's shares surged 20.6% following Merck's announcement of a $10 billion acquisition deal.
Notable Stock Gains: Several companies saw significant stock price increases, including Scage Future (up 55.4%), ProKidney Corp (up 47.1%), and Rhythm Pharmaceuticals (up 25.8%) after positive trial results.
